Arcutis Biotherapeutics Inc

NASDAQ:ARQT   3:50:02 PM EDT
15.40
-0.49 (-3.08%)
Products

FDA Accepts Arcutis Biotherapeutics’ New Drug Application For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis

Published: 12/22/2021 21:12 GMT
Arcutis Biotherapeutics Inc (ARQT) - FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents With Plaque Psoriasis.
Arcutis Biotherapeutics Inc - FDA Has Set a Target Action Date of July 29, 2022.